INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 S...

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and ...

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update...

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alz...

INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on We...

INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series...

INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences...

Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evi...

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK C...

INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference...

INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference...

INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update...

INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on W...

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New P...

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association Int...

Inmune Bio, Inc. Announces $40 Million Registered Direct Offering...

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in Hi...

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Di...

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin fro...

INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted b...

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update...

INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on We...

INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference...

INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming...

INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021...

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update...

INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corpora...

INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomar...

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET...